Download PDF
Thromb Haemost 2006; 95(04): 668-677
DOI: 10.1160/TH05-11-0757
Endothelium and Vascular Development
Schattauer GmbH

Anti-angiogenesis mediated by angiostatin K1–3, K1–4 and K1–4.5

Involvement of p53, FasL, AKT and mRNA deregulation
Ya-Huey Chen
1   Institute of Basic Medical Sciences
,
Hua-Lin Wu
2   Department of Biochemistry and Molecular Biology
4   Cardiovascular Research Center, College of Medicine, National Cheng Kung University, Taiwan, Republic of China
,
Ching Li
5   Department of Applied Microbiology, National Chai-Yi University, Taiwan, Republic of China
,
Yi-Hsien Huang
1   Institute of Basic Medical Sciences
,
Chi-Wu Chiang
3   Institute of Molecular Medicine, and
,
Ming-Ping Wu
6   Department of Obstetrics and Gynecology, Chi-Mei Foundation Hospital, Yung Kang, Taiwan, Republic of China
,
Li-Wha Wu
3   Institute of Molecular Medicine, and
4   Cardiovascular Research Center, College of Medicine, National Cheng Kung University, Taiwan, Republic of China
› Author AffiliationsFinancial support: This work was supported by National Science Council (NSC93-2320-B006), National Health Research Institute (NHRI-EX92-9016BC) and the MOE program promoting academic excellence of University under the grant number (91-B-FA09-2-4) in Taiwan.
Further Information

Publication History

Received 23 November 2005

Accepted after revision 21 February 2006

Publication Date:
02 December 2017 (online)

    Permissions and Reprints

Summary

The molecular mechanism mediated by multiple forms of angiostatin via acting on proliferating vascular endothelium remains elusive. To address whether three forms of angiostatin, K1-3, K1-4 or K1-4.5, utilized similar or distinct pathways to mediate anti-angiogenesis, we adopted an adenoviral expression system to express secretable angiostatin molecules for CM collection. The anti-angiogenic activity of K1-3, K1-4 or K1-4.5 was confirmed by using proliferation, migration, tube formation and apoptotic assays of human endothelial cells. These angiostatin molecules at comparable expression level inhibited various in vitro angiogenesis assays with some variations. Furthermore, K1-3, K1-4 or K1-4.5 increased the expression of p53 protein and its downstream effectors, enhanced FasL-mediated signaling pathways, and decreased activation of AKT. At least three different receptors, Fas, integrin αvβ3 and ATP synthase, were involved in the anti-angiogenic action of angiostatin molecules. Besides, the expression of 189 genes at mRNA level was significantly altered by K1-3, K1-4 or K1-4.5. More than 70% of these genes participate in growth, inflammation, apoptosis, migration and extracellular matrix. Taken together, K1-3, K1-4 and K1-4.5, regardless of the number of kringles in the angiostatin molecules, mediated anti-angiogenesis via mostly similar pathways. We are the first to demonstrate the involvement of DAPK1 in the mediation of anti-angiogenesis by angiostatin.

Keywords

Angiostatin - endothelial cells - AKT - p53 - FasL

 

  • References

  • 1 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med 1995; 01: 27-31.
    CrossrefPubMedGoogle Scholar
  • 2 Mauceri HJ, Hanna NN, Beckett MA. et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998; 394: 287-91.
    CrossrefPubMedGoogle Scholar
  • 3 Zondor SD, Medina PJ. Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004; 38: 1258-64.
    CrossrefPubMedGoogle Scholar
  • 4 O’Reilly MS, Holmgren L, Shing Y. et al. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol 1994; 59: 471-82.
    CrossrefPubMedGoogle Scholar
  • 5 Cao Y, Ji RW, Davidson D. et al. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells.J Biol Chem 1996; 271: 29461-7.
    PubMedGoogle Scholar
  • 6 MacDonald NJ, Murad AC, Fogler WE. et al. The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3. Biochem Biophys Res Commun 1999; 264: 469-77.
    CrossrefPubMedGoogle Scholar
  • 7 Soff GA. Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev 2000; 19: 97-107.
    CrossrefPubMedGoogle Scholar
  • 8 Cao R, Wu HL, Veitonmaki N. et al. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci USA 1999; 96: 5728-33.
    CrossrefPubMedGoogle Scholar
  • 9 Griscelli F, Li H, Bennaceur-Griscelli A. et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 1998; 95: 6367-72.
    CrossrefPubMedGoogle Scholar
  • 10 Claesson-Welsh L, Welsh M, Ito N. et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrinbinding motif RGD. Proc NatlAcad Sci USA 1998; 95: 5579-83.
    CrossrefPubMedGoogle Scholar
  • 11 Redlitz A, Daum G, Sage EH. Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells. J Vasc Res 1999; 36: 28-34.
    CrossrefPubMedGoogle Scholar
  • 12 Luo J, Lin J, Paranya G. et al. Angiostatin upregulates E-selectin in proliferating endothelial cells. Biochem Biophys Res Commun 1998; 245: 906-11.
    CrossrefPubMedGoogle Scholar
  • 13 Sharma MR, Tuszynski GP, Sharma MC. Angiostatin-induced inhibition of endothelial cell proliferation/ apoptosis is associated with the down-regulation of cell cycle regulatory protein cdk5. J Cell Biochem 2004; 91: 398-409.
    CrossrefPubMedGoogle Scholar
  • 14 Chavakis T, Athanasopoulos A, Rhee JS. et al. Angiostatin is a novel anti-inflammatory factor by inhibiting leukocyte recruitment. Blood 2005; 105: 1036-43.
    PubMedGoogle Scholar
  • 15 Wajih N, Sane DC. Angiostatin selectively inhibits signaling by hepatocyte growth factor in endothelial and smooth muscle cells. Blood 2003; 101: 1857-63.
    CrossrefPubMedGoogle Scholar
  • 16 Moser TL, Stack MS, Asplin I. et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 1999; 96: 2811-6.
    CrossrefPubMedGoogle Scholar
  • 17 Moser TL, Kenan DJ, Ashley TA. et al. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci USA 2001; 98: 6656-61.
    CrossrefPubMedGoogle Scholar
  • 18 Tarui T, Miles LA, Takada Y. Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J Biol Chem 2001; 276: 39562-8.
    CrossrefPubMedGoogle Scholar
  • 19 Wang H, Schultz R, Hong J. et al. Cell surface-dependent generation of angiostatin4.5. Cancer Res 2004; 64: 162-8.
    CrossrefPubMedGoogle Scholar
  • 20 Lucas R, Holmgren L, Garcia I. et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998; 92: 4730-41.
    PubMedGoogle Scholar
  • 21 Chen YH, Wu HL, Chen CK. et al. Angiostatin antagonizes the action of VEGF-A in human endothelial cells via two distinct pathways. Biochem Biophys Res Commun 2003; 310: 804-10.
    CrossrefPubMedGoogle Scholar
  • 22 Hanford HA, Wong CA, Kassan H. et al. Angiostatin(4.5)-mediated apoptosis of vascular endothelial cells. Cancer Res 2003; 63: 4275-80.
    PubMedGoogle Scholar
  • 23 Veitonmaki N, Cao R, Wu LH. et al. Endothelial cell surface ATP synthase-triggered caspase-apoptotic pathway is essential for k1-5-induced anti-angiogenesis. Cancer Res 2004; 64: 3679-86.
    CrossrefPubMedGoogle Scholar
  • 24 Jih Y-J, Lien W-H, Tsai W-C. et al. Distinct regulation of genes by bFGF and VEGF-A in endothelial cells. Angiogenesis 2001; 04: 313-21.
    CrossrefPubMedGoogle Scholar
  • 25 Gyorffy S, Palmer K, Gauldie J. Adenoviral vector expressing murine angiostatin inhibits a model of breast cancer metastatic growth in the lungs of mice. Am J Pathol 2001; 159: 1137-47.
    CrossrefPubMedGoogle Scholar
  • 26 Miyashita T, Reed J. C Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-9.
    CrossrefPubMedGoogle Scholar
  • 27 Martoriati A, Doumont G, Alcalay M. et al. dapk1, encoding an activator of a p19ARF-p53-mediated apoptotic checkpoint, is a transcription target of p53. Oncogene 2005; 24: 1461-6.
    CrossrefPubMedGoogle Scholar
  • 28 Volpert OV, Zaichuk T, Zhou W. et al. Inducer-stimulated fas targets activated endothlelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002; 08: 349-57.
    CrossrefPubMedGoogle Scholar
  • 29 Kaneko Y, Kitazato K, Basaki Y. Integrin-linked kinase regulates vascular morphogenesis induced by vascular endothelial growth factor. J Cell Sci 2004; 117: 407-15.
    PubMedGoogle Scholar
  • 30 Tarui T, Miles LA, Takada Y. Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J Biol Chem 2001; 276: 39562-8.
    CrossrefPubMedGoogle Scholar
  • 31 Osborn L, Hession C, Tizard R. et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989; 59: 1203-11.
    CrossrefPubMedGoogle Scholar
  • 32 Pollman MJ, Naumovski L, Gibbons GH. Endothelial cell apoptosis in capillary network remodeling. J Cell Physiol 1999; 178: 359-70.
    CrossrefPubMedGoogle Scholar
  • 33 Levy-Strumpf N, Kimchi A. Death associated proteins (DAPs): from gene identification to the analysis of their apoptotic and tumor suppressive functions. Oncogene 1998; 17: 3331-40.
    CrossrefPubMedGoogle Scholar
  • 34 Kogel D, Prehn JH, Scheidtmann KH. The DAP kinase family of pro-apoptotic proteins: novel players in the apoptotic game. Bioessays 2001; 23: 352-8.
    CrossrefPubMedGoogle Scholar
  • 35 Eriksson K, Magnusson P, Dixelius J. et al. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett 2003; 536: 19-24.
    CrossrefPubMedGoogle Scholar
  • 36 Morikawa W, Yamamoto K, Ishikawa S. et al. Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells. J Biol Chem 2000; 275: 38912-20.
    CrossrefPubMedGoogle Scholar
  • 37 Luo J, Lin J, Paranya G. et al. Angiostatin upregulates E-selectin in proliferating endothelial cells. Biochem Biophys Res Commun 1998; 245: 906-11.
    CrossrefPubMedGoogle Scholar
  • 38 Nguyen M, Strubel NA, Bischoff J. A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis. Nature 1993; 365: 267-9.
    CrossrefPubMedGoogle Scholar
  • 39 Kraling BM, Razon MJ, Boon LM. et al. E-selectin is present in proliferating endothelial cells in human hemangiomas. Am J Pathol 1996; 148: 1181-91.
    PubMedGoogle Scholar
  • 40 Yu Y, Moulton KS, Khan MK. et al. E-selectin is required for the antiangiogenic activity of endostatin. Proc Natl Acad Sci USA 2004; 101: 8005-10.
    CrossrefPubMedGoogle Scholar
  • 41 O’Reilly MS, Holmgren L, Shing Y. et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases bya Lewis lung carcinoma. Cell 1994; 79: 315-28.
    CrossrefPubMedGoogle Scholar
  • 42 O’Reilly MS, Holmgren L, Chen C. et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 02: 689-92.
    CrossrefPubMedGoogle Scholar
  • 43 Cao R, Wu HL, Veitonmaki N. et al. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci USA 1999; 96: 5728-33.
    CrossrefPubMedGoogle Scholar